ResMed (RMD) Stock Forecast & Price Target

Q: What analysts cover ResMed?

ResMed has been rated by research analysts at Citigroup , Jefferies Financial Group , KeyCorp , Mizuho , Piper Sandler , Robert W. Baird , Rothschild & Co Redburn , Royal Bank Of Canada , The Goldman Sachs Group , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$222.38 +0.38 (+0.17%)

Closing price 03:59 PM Eastern

Extended Trading

$222.16 -0.23 (-0.10%)

As of 07:30 PM Eastern

Compare

ResMed - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 16 Analyst Ratings

Sell
0

Hold
9

Buy
7

Based on 16 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 9 have given a hold rating, and 7 have given a buy rating for RMD.

Consensus Price Target

$241.69
8.68% Upside

According to the 16 analysts' twelve-month price targets for ResMed, the average price target is $241.69. The highest price target for RMD is $300.00, while the lowest price target for RMD is $213.00. The average price target represents a forecasted upside of 8.68% from the current price of $222.38.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RMD Analyst Ratings Over Time

Type	Current Forecast 9/28/25 to 9/28/26	1 Month Ago 8/29/25 to 8/29/26	3 Months Ago 6/30/25 to 6/30/26	1 Year Ago 9/28/24 to 9/28/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	10 Buy rating(s)
Hold	9 Hold rating(s)	10 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$241.69	$239.38	$270.82	$294.20
Forecasted Upside	8.68% Upside	-0.45% Downside	38.85% Upside	8.75% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Healthcare Companies	Broader Market
Consensus Rating Score	2.44	2.31	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	8.68% Upside	780.15% Upside	19.95% Upside
News Sentiment Rating	Positive News See Recent RMD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/15/2026	Royal Bank Of Canada 3 of 5 stars	Craig Wong-Pan Not Rated	Upgrade	Sector Perform ➝ Outperform	$244.00 ➝ $262.00	+17.46%
9/10/2026	Citigroup 4 of 5 stars	Laura Sutcliffe Not Rated	Reiterated Rating	Neutral
8/31/2026	KeyCorp 2 of 5 stars	Brett Fishbin 1 of 5 stars	Boost Target	Overweight	$255.00 ➝ $267.00	+11.03%
8/19/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jackson Philips Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$230.00	+4.42%
8/11/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C-) ➝ Hold (C)
8/7/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$213.00	-1.07%
8/7/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$233.00 ➝ $225.00	+7.36%
8/7/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nathan Treybeck Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$225.00 ➝ $215.00	+1.80%
7/21/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$300.00	+53.10%
7/15/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$235.00 ➝ $220.00	+12.30%
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
7/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$240.00 ➝ $225.00	+9.78%
7/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
6/17/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Bailey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$286.00 ➝ $230.00	+18.48%
4/15/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Low Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight
4/13/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$255.00	+11.52%
1/30/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$260.00 ➝ $265.00	+2.78%
9/2/2025	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Outperform
8/1/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
1/31/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:08 PM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 28, 2026. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. recently received an upgrade to an "Outperform" rating from RBC Capital Markets, which raised its price target to $262.00, signaling strong confidence in the company's ability to capture market share following setbacks experienced by competitors in the sleep apnea treatment sector.
The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $2.95, which beat the consensus estimate of $2.89, while also achieving a net margin of 26.94% and a return on equity of 25.58%, indicating efficient capital management and profitability.
ResMed Inc. has increased its quarterly dividend to $0.66 per share, representing a 10% increase from the previous $0.60 payout, which provides a yield of approximately 1.2% and reflects management's commitment to returning value to shareholders while maintaining a sustainable payout ratio of 25.31%.
With the current stock price at $222.38, the shares are trading below the average 12-month price target of $241.69 set by sixteen ratings firms, suggesting potential upside for investors as the consensus recommendation remains a "Hold" with seven buy ratings and nine hold ratings.
Recent institutional activity shows positive momentum, with State Street Corp increasing its stake by 0.6% to over 6.6 million shares, and new investments from entities like Nykredit A S and Bank of America Corp DE, indicating growing institutional interest in the company's long-term growth prospects in respiratory care.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

Insider selling has been consistent, with CEO Michael J. Farrell and Director Peter C. Farrell executing multiple sales of thousands of shares in recent months, including a sale by the CEO of 4,991 shares at an average price of $222.44 in September 2026, which may signal reduced internal confidence or personal financial planning rather than a bullish outlook.
The stock has experienced significant volatility and recent declines, including a gap down of 16.06 points on August 7, 2026, and trading near its 52-week low of $180.26 earlier in the year, reflecting market uncertainty and potential pressure on the valuation despite the current recovery to $222.38.
Short interest has increased, with shares shorted rising to 14.2 million as of September 15, 2026, representing approximately 9.9% of the float, and days to cover increasing to 11.74, indicating that a significant portion of the market is betting against the stock's future performance.
ResMed Inc. faces rising competitive pressures and margin challenges from increasing costs, as highlighted by recent analyst discussions, which could erode the company's profitability and limit its ability to maintain high growth rates in the sleep and respiratory care markets.
The company's beta of 0.77 suggests lower volatility than the market, but the recent drop in consensus price targets from $299.27 in early 2026 to $241.69 currently indicates a downward revision in analyst expectations, reflecting a more cautious outlook on the company's future earnings potential.

RMD Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $241.69, with a high forecast of $300.00 and a low forecast of $213.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 9 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.

According to analysts, ResMed's stock has a predicted upside of 8.68% based on their 12-month stock forecasts.

Over the previous 90 days, ResMed's stock had 3 downgrades and 2 upgrades by analysts.

ResMed has been rated by research analysts at Citigroup, Jefferies Financial Group, KeyCorp, Mizuho, Piper Sandler, Robert W. Baird, Rothschild & Co Redburn, Royal Bank Of Canada, The Goldman Sachs Group, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like ResMed more than other "healthcare" companies. The consensus rating score for ResMed is 2.44 while the average consensus rating score for "healthcare" companies is 2.31. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With ResMed Recommendations

MarketBeat monitors more than a dozen sources for ResMed analyst ratings, with the most recent rating issued on 9/15/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target